株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ギラン・バレー症候群:パイプライン製品の分析

Guillain-Barre Syndrome - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 332891
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.11円で換算しております。
ギラン・バレー症候群:パイプライン製品の分析 Guillain-Barre Syndrome - Pipeline Review, H2 2019
出版日: 2019年12月05日 ページ情報: 英文 61 Pages
概要

ギラン・バレー症候群 (GBS) とは、体内の免疫システムが末梢神経系の一部を攻撃するために、最初に程度の差はあるものの足の筋力低下やチクチクする感覚が現れてきます。多くの場合、腕や上半身に左右対称的な筋力低下や感覚異常が広がっていきます。こうした症状は、特定の筋肉が全く動かなくなるまで続き、ひどい時はほとんど全身が麻痺してしまうこともあります。危険因子としてはインフルエンザ・ウィルス、マイコプラズマ肺炎、ホジキンリンパ腫、エプスタイン・バー・ウイルスなどが挙げられます。

当レポートでは、世界におけるギラン・バレー症候群のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発の進展状況)、最新の業界動向などを調査した結果をお届けします。

イントロダクション

  • 調査範囲
  • ギラン・バレー症候群 概要

治療薬の開発

  • パイプライン製品;ギラン・バレー症候群;概要
  • 企業で開発中の治療薬
  • 大学/機関で研究中の治療薬
  • 企業で開発中の製品
  • 大学/機関で研究中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Akari Therapeutics Plc
  • Annexon Inc
  • CuraVac Inc
  • Hansa Medical AB
  • Regenesance BV
  • Vitality Biopharma Inc

薬剤プロファイル

休止中のプロジェクト

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Guillain-Barre Syndrome, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Guillain-Barre Syndrome - Pipeline by Akari Therapeutics Plc, H2 2019
  • Guillain-Barre Syndrome - Pipeline by Annexon Inc, H2 2019
  • Guillain-Barre Syndrome - Pipeline by Cellenkos Inc, H2 2019
  • Guillain-Barre Syndrome - Pipeline by Complement Pharma BV, H2 2019
  • Guillain-Barre Syndrome - Pipeline by CuraVac Inc, H2 2019
  • Guillain-Barre Syndrome - Pipeline by Hansa Biopharma AB, H2 2019
  • Guillain-Barre Syndrome - Pipeline by Vitality Biopharma Inc, H2 2019
  • Guillain-Barre Syndrome - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Guillain-Barre Syndrome, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11602IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2019, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.

Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 2, 1 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Guillain-Barre Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Guillain-Barre Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Guillain-Barre Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Guillain-Barre Syndrome - Overview
  • Guillain-Barre Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Guillain-Barre Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Guillain-Barre Syndrome - Companies Involved in Therapeutics Development
  • Akari Therapeutics Plc
  • Annexon Inc
  • Cellenkos Inc
  • Complement Pharma BV
  • CuraVac Inc
  • Hansa Biopharma AB
  • Vitality Biopharma Inc
  • Guillain-Barre Syndrome - Drug Profiles
  • ANX-005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CK-0801 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CP-010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • imlifidase - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nomacopan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine for Guillain-Barre Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Guillain-Barre Syndrome - Dormant Projects
  • Guillain-Barre Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Apr 15, 2019: Hansa Biopharma receives ethics and regulatory clearance to start Phase 2 study of imlifidase in Guillain Barre Syndrome
  • Feb 16, 2018: Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barre syndrome
  • Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome
  • May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barre Syndrome
  • May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barre Syndrome
  • Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
  • Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
  • Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer